Recruiting

Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients

ClinicalTrials.gov IDNCT06991712

PhasePHASE2

Enrollment138

SponsorChristopher Kai Shun Leung

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Glaucoma

About this study

The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-angle glaucoma. The main questions it aims to answer are: 1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term? 2. How do plasma NAD+ metabolite profiles change after administration of each precursor, and do these changes relate to improvements in visual function? Researchers will compare NR, NAM, NMN, NA, and placebo groups to see if any of the NAD precursors lead to greater improvements in visual field sensitivity or changes in blood NAD+ metabolite levels compared to placebo. Participants will: Be randomly assigned to receive one of the four NAD precursors or placebo daily for two weeks. Undergo comprehensive eye examinations, including visual field testing and optical coherence tomography, at baseline and after two weeks. Provide blood samples before and after the intervention for measurement of NAD+ metabolites. Have safety monitored through clinical examination. This study will help identify whether boosting NAD+ levels with specific precursors offers functional benefit in glaucoma, and which blood metabolites may mediate these effects.

Interventions

Dietary Supplement: Nicotinamide Riboside — Oral supplementation of 300mg Nicotinamide Riboside (NR) daily for 2 weeks
Dietary Supplement: Nicotinamide — Oral supplementation of 125mg Nicotinamide/Niacinamide (NAM) daily for 2 weeks
Dietary Supplement: Nicotinamide Mononucleotide — Oral supplementation of 350mg Nicotinamide Mononucleotide (NMN) daily for 2 weeks
Dietary Supplement: Nicotinic Acid — Oral supplementation of 350mg Nicotinic Acid (NA) daily for 2 weeks
Other: Placebo (Corn Starch) — Oral supplementation of 300mg Placebo daily for 2 weeks
Other: Placebo (Corn Starch) — Oral supplementation of 300mg Placebo daily for 2 weeks

Primary outcomes

Change in visual field sensitivity (2 weeks)

Eligibility information

Inclusion Criteria: * glaucoma patients * age ≥ 18 years * best corrected VA ≥20/40 * IOP \<21 mmHg * visual field mean deviation better than -24 dB on standard automated perimetry 24-2 SITA standard Exclusion Criteria: * pathological myopia * diseases that may cause visual field loss or optic disc abnormalities other than glaucoma * inability to perform reliable visual field * suboptimal quality of OCT images * diabetic retinopathy/maculopathy * history of abnormal liver function within 12 months * known allergy to NAD precursor supplement(s) * pregnancy or lactation * use of NAD precursor supplements 14 days prior to baseline.

Study locations

HKU Eye Centre, Wong Chuk Hang, Hong Kong

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.